Immunmodulatorische Effekte von TLR3- und TLR7-Liganden auf die Pathogenese des chronischenAsthma bronchiale im Maus-Modell

Das allergische Asthma bronchiale ist eine komplexe Erkrankung der Lunge, die mit einer bronchialen chronischen Hyperreagibilität, Entzündungsreaktion der Atemwegsobstruktion Atemwege, sowie einer strukturellen Veränderungen der Lunge im Sinne eines Airway remodelling assoziiert ist. Eine zentra...

Full description

Saved in:
Bibliographic Details
Main Author: Sel, Sarper
Contributors: Rothemund, Matthias (Prof. Dr.) (Thesis advisor)
Format: Dissertation
Published: Philipps-Universität Marburg 2010
Online Access:PDF Full Text
Tags: Add Tag
No Tags, Be the first to tag this record!

1. Wills-Karp M, Luyimbazi J, Xu X, Schofield B, Neben TY, Karp CL, Donaldson DD. 1998. Interleukin-13: central mediator of allergic asthma. Science 282(5397):2258-2261.

2. Testerman TL, Gerster JF, Imbertson LM, Reiter MJ, Miller RL, Gibson SJ, Wagner TL, Tomai MA. 1995. Cytokine induction by the immunomodulators imiquimod and S-27609. JLeukocBiol 58(3):365-372.

3. Reiter MJ, Testerman TL, Miller RL, Weeks CE, Tomai MA. 1994. Cytokine induction in mice by the immunomodulator imiquimod. JLeukocBiol 55(2):234-240.

4. von Mutius E, Illi S, Hirsch T, Leupold W, Keil U, Weiland SK. 1999. Frequency of infections and risk of asthma, atopy and airway hyperresponsiveness in children. EurRespirJ 14(1):4-11.

5. Schmitt E, Van Brandwijk R, Fischer HG, Rude E. 1990. Establishment of different T cell sublines using either interleukin 2 or interleukin 4 as growth factors. Eur J Immunol 20(8):1709-1715.

6. Stavnezer J. 1996. Immunoglobulin class switching. CurrOpinImmunol 8(2):199- 205.

7. Effective prevention and therapy of experimental allergic asthma using a GATA-3-specific DNAzyme.

8. Wegmann M, Fehrenbach H, Fehrenbach A, Held T, Schramm C, Garn H, Renz H. 2005. Involvement of distal airways in a chronic model of experimental asthma. Clin Exp Allergy 35(10):1263-1271.

9. Sukkar MB, Xie S, Khorasani NM, Kon OM, Stanbridge R, Issa R, Chung KF. 2006. Toll-like receptor 2, 3, and 4 expression and function in human airway smooth muscle. J Allergy Clin Immunol 118(3):641-648.

10. Shen E, Lu L, Wu C. 2008. TLR7/8 ligand, R-848, inhibits IgE synthesis by acting directly on B lymphocytes. Scand J Immunol 67(6):560-568.

11. Ring J. 1985. [1st description of an "atopic family anamnesis" in the Julio- Claudian imperial house: Augustus, Claudius, Britannicus]. Hautarzt 36(8):470-471.

12. Seder RA, Paul WE. 1994. Acquisition of lymphokine-producing phenotype by CD4+ T cells. Annu Rev Immunol 12:635-673.

13. Vasilakos JP, Smith RM, Gibson SJ, Lindh JM, Pederson LK, Reiter MJ, Smith MH, Tomai MA. 2000a. Adjuvant activities of immune response modifier R-848: comparison with CpG ODN. Cell Immunol 204(1):64-74.

14. Ring J. 1997. Allergy and modern society: does 'Western life style' promote the development of allergies? IntArchAllergy Immunol 113(1-3):7-10.

15. Wegmann M. 2008. Animal models of chronic experimental asthma -strategies for the identification of new therapeutic targets. J Occup Med Toxicol 3

16. Wegmann M, Renz H. 2005. Animal models of experimental asthma. Ernst Schering Res Found Workshop(50):69-87.

17. Annual Meeting of the Austrian Society for Allergology and Immunology from 1st-3rd December 2005 in Graz, Austria

18. Wegmann, M.; Goeggel, R.; Sel, S.; Erb, K.J.; Kalkbrenner, F.; Garn, H.; Renz, H. Antagonisation of CCR-3 Results in Reduction of Airway Hyperresponsiveness and Airway Remodelling in a Mouse Model of Chronic Experimental Asthma.

19. Schöll I, Ackermann U, Özdemir C, Blümer N, Dicke T, Sel S, Sel S, Wegmann M, Untersmayr E, Renz H, Garn H, Jensen-Jarolim E. Anti-acid medication supports sensitization to food antigens in pregnant mothers and the perinatal Th2 environment in newborns: a BALB/c mouse model Annual Meeting of the Austrian Society for Nutrition, Vienna, 18-19th November 2005

20. Anti-acid treatment of pregnant females induces sensitization and a perinatal TH2-biased immune response also in the offspring; a BALB/c mouse model.

21. Smith EB, Schwartz M, Kawamoto H, You X, Hwang D, Liu H, Scherr DS. 2007. Antitumor effects of imidazoquinolines in urothelial cell carcinoma of the bladder. JUrol 177(6):2347-2351.

22. Suzaki Y, Hamada K, Nomi T, Ito T, Sho M, Kai Y, Nakajima Y, Kimura H. 2008. A small-molecule compound targeting CCR5 and CXCR3 prevents airway hyperresponsiveness and inflammation. Eur Respir J 31(4):783- 789.

23. Association of the ADAM33 gene with asthma and bronchial hyperresponsiveness. Nature 418(6896):426-430.

24. Zhang D, Zhang G, Hayden MS, Greenblatt MB, Bussey C, Flavell RA, Ghosh S. 2004. A toll-like receptor that prevents infection by uropathogenic bacteria. Science 303(5663):1522-1526.

25. Attenuation of Experimental Asthma Pathology by TLR-3 Activation partially depends on IL-12.

26. Riedler J, Eder W, Oberfeld G, Schreuer M. 2000. Austrian children living on a farm have less hay fever, asthma and allergic sensitization. ClinExpAllergy 30(2):194-200.

27. Rodriguez D, Keller AC, Faquim-Mauro EL, de Macedo MS, Cunha FQ, Lefort J, Vargaftig BB, Russo M. 2003. Bacterial lipopolysaccharide signaling 6. Referenzen 99 through Toll-like receptor 4 suppresses asthma-like responses via nitric oxide synthase 2 activity. JImmunol 171(2):1001-1008.

28. Romagnani S. 1995. Biology of human TH1 and TH2 cells. J Clin Immunol 15(3):121-129.

29. CD4(+) T cells from mice with intestinal immediate-type hypersensitivity induce airway hyperreactivity.

30. Taylor B, Wadsworth J, Wadsworth M, Peckham C. 1984. Changes in the reported prevalence of childhood eczema since the 1939-45 war. Lancet 2(8414):1255-1257.

31. Ritter M, Mennerich D, Weith A, Seither P. 2005a. Characterization of Toll-like receptors in primary lung epithelial cells: strong impact of the TLR3 ligand poly(I:C) on the regulation of Toll-like receptors, adaptor proteins and inflammatory response. J Inflamm (Lond) 2:16.

32. Smith SM. 1997. Conference review: 'towards self-management of asthma-- whose asthma is it anyway?'. Collegian 4(2):46.

33. Uthoff H, Spenner A, Reckelkamm W, Ahrens B, Wolk G, Hackler R, Hardung F, Schaefer J, Scheffold A, Renz H, Herz U. 2003. Critical role of preconceptional immunization for protective and nonpathological specific immunity in murine neonates. J Immunol 171(7):3485-3492.

34. Der therapeutische Effekt des TLR-7-Liganden Resiquimod auf das experimentelle Asthma ist IL-12-abhängig.

35. Die Supression von etabliertem Asthma mittels TLR-7-Liganden R-848 ist teilweise IL-12 abhängig. Allergo Journal. 14(1): 38, 2005.

36. Wegmann M, Goggel R, Sel S, Sel S, Erb KJ, Kalkbrenner F, Renz H, Garn H. Effects of a low-molecular-weight CCR-3 antagonist on chronic experimental asthma.

37. von Mutius E, Braun-Fahrlander C, Schierl R, Riedler J, Ehlermann S, Maisch S, Waser M, Nowak D. 2000. Exposure to endotoxin or other bacterial components might protect against the development of atopy. ClinExpAllergy 30(9):1230-1234.

38. Riedler J, Braun-Fahrlander C, Eder W, Schreuer M, Waser M, Maisch S, Carr D, Schierl R, Nowak D, von Mutius E. 2001. Exposure to farming in early life and development of asthma and allergy: a cross-sectional survey. Lancet 358(9288):1129-1133.

39. Strachan DP. 2000. Family size, infection and atopy: the first decade of the "hygiene hypothesis". Thorax 55 Suppl 1:S2-10.

40. Buchbeiträge Immunomodulatory Effects of Viral Toll-Like Receptor Ligands M. Wegmann, S. Sel, S. Sel, S. Bauer, H. Renz, and H. Garn Cellular and Molecular Targets in Allergy and Clinical Immunology by Stephen T. Holgate, Gianni Marone, Johannes Ring (Editors) Hogrefe & Huber Publishers, Cambridge, USA (2008)

41. Wallen N, Kita H, Weiler D, Gleich GJ. 1991. Glucocorticoids inhibit cytokine- mediated eosinophil survival. J Immunol 147(10):3490-3495.

42. Sampson AP. 2001. IL-5 priming of eosinophil function in asthma. ClinExpAllergy 31(4):513-517.

43. Wigbels B, Luger T, Metze D. 2001. [Imiquimod: a new treatment possibility in bowenoid papulosis?]. Hautarzt 52(2):128-131.

44. Sel S, Wegmann M, Bauer S, Garn H, Alber G, Renz H. 2007. Immunomodulatory effects of viral TLR ligands on experimental asthma depend on the additive effects of IL-12 and IL-10. J Immunol 178(12):7805-7813.

45. Youn CJ, Miller M, Baek KJ, Han JW, Nayar J, Lee SY, McElwain K, McElwain S, Raz E, Broide DH. 2004. Immunostimulatory DNA reverses established allergen-induced airway remodelling. J Immunol 173(12):7556-7564.

46. Weiner HL. 2001. Induction and mechanism of action of transforming growth factor-beta-secreting Th3 regulatory cells. ImmunolRev 182:207-214.

47. Stock P, Akbari O, Berry G, Freeman GJ, DeKruyff RH, Umetsu DT. 2004. Induction of T helper type 1-like regulatory cells that express Foxp3 and protect against airway hyper-reactivity. NatImmunol 5(11):1149-1156.

48. Stock P, DeKruyff RH, Umetsu DT. 2006. Inhibition of the allergic response by regulatory T cells. CurrOpinAllergy ClinImmunol 6(1):12-16.

49. Staros EB. 2005. Innate immunity: New approaches to understanding its clinical significance. AmJClinPathol 123(2):305-312.

50. Assistenzarzt am Klinikum der Universität München; Institut für Klinische Chemie; Prof. Dr. Seidel

51. Takeuchi O, Hemmi H, Akira S. 2004. Interferon response induced by Toll-like receptor signaling. J Endotoxin Res 10(4):252-256.

52. Schöll, I.; Ackermann, U.; Özdemir, C.; Blümer, N.; Dicke, T.; Sel, S.; Sel, S.; Wegmann M.; Untersmayr E.; Garn H.; Jensen-Jarolim E.; Renz H. Treatment of Pregnant Females with Anti-Acids Induces Sensitization in Mothers and a Perinatal Th2-Dominated Immune Response in Offsprings: a BALB/c Mouse Model.

53. Hämatologie, Klinische Immunologie und Rheumatologie; Prof. Dr. Pfreundschuh seit 10/2006

54. LPS-stimulated SJL macrophages produce IL-12 and IL-18 that inhibit IgE production in vitro by induction of IFN-gamma production from CD3intIL-2R beta+ T cells. JImmunol 161(3):1483-1492.

55. Shaheen SO, Aaby P, Hall AJ, Barker DJ, Heyes CB, Shiell AW, Goudiaby A. 1996. Measles and atopy in Guinea-Bissau. Lancet 347(9018):1792- 1796.

56. Zhou X, Hu H, Huynh ML, Kotaru C, Balzar S, Trudeau JB, Wenzel SE. 2007. Mechanisms of tissue inhibitor of metalloproteinase 1 augmentation by IL-13 on TGF-beta 1-stimulated primary human fibroblasts. J Allergy Clin Immunol 119(6):1388-1397.

57. Sabet M, Cottam HB, Guiney DG. 2006. Modulation of cytokine production and enhancement of cell viability by TLR7 and TLR9 ligands during anthrax infection of macrophages. FEMS Immunol Med Microbiol 47(3):369-379.

58. Zhu FG, Kandimalla ER, Yu D, Tang JX, Agrawal S. 2004. Modulation of ovalbumin-induced Th2 responses by second-generation immunomodulatory oligonucleotides in mice. Int Immunopharmacol 4(7):851-862.

59. Wagner TL, Ahonen CL, Couture AM, Gibson SJ, Miller RL, Smith RM, Reiter MJ, Vasilakos JP, Tomai MA. 1999. Modulation of TH1 and TH2 cytokine 6. Referenzen 104 production with the immune response modifiers, R-848 and imiquimod.

60. Trinchieri G, Wysocka M, D'Andrea A, Rengaraju M, Aste-Amezaga M, Kubin M, Valiante NM, Chehimi J. 1992. Natural killer cell stimulatory factor (NKSF) or interleukin-12 is a key regulator of immune response and inflammation. ProgGrowth Factor Res 4(4):355-368.

61. Talay F, Kurt B, Tug T, Yilmaz F, Goksugur N. 2008. Prevalence and risk factors of asthma and allergic diseases among schoolchildren in Bolu, Turkey. Acta Paediatr 97(4):459-462.

62. Varjonen E, Kalimo K, Lammintausta K, Terho P. 1992. Prevalence of atopic disorders among adolescents in Turku, Finland. Allergy 47(3):243-248.

63. Yamaguchi Y, Suda T, Suda J, Eguchi M, Miura Y, Harada N, Tominaga A, Takatsu K. 1988b. Purified interleukin 5 supports the terminal differentiation and proliferation of murine eosinophilic precursors. J Exp Med 167(1):43-56.

64. Salisbury BA, Pungliya M, Choi JY, Jiang R, Sun XJ, Stephens JC. 2003. SNP and haplotype variation in the human genome. MutatRes 526(1-2):53-61.

65. Supression of Experimental Asthma by Toll-like Receptor 3 Activation Requires IL-12.

66. Romagnani S. 2000. T-cell subsets (Th1 versus Th2). AnnAllergy Asthma Immunol 85(1):9-18.

67. Wegmann M. 2009. Th2 cells as targets for therapeutic intervention in allergic bronchial asthma. Expert Rev Mol Diagn 9(1):85-100.

68. Rutten van-Molken MP, Feenstra TL. 2001. The burden of asthma and chronic obstructive pulmonary disease: data from The Netherlands. Pharmacoeconomics 19 Suppl 2:1-6.

69. Zar HJ, Ehrlich RI, Workman L, Weinberg EG. 2007. The changing prevalence of asthma, allergic rhinitis and atopic eczema in African adolescents from 1995 to 2002. PediatrAllergy Immunol 18(7):560-565.

70. Schernhammer ES, Vutuc C, Waldhor T, Haidinger G. 2008. Time trends of the prevalence of asthma and allergic disease in Austrian children. PediatrAllergy Immunol 19(2):125-131.

71. Yamamoto M, Takeda K, Akira S. 2004. TIR domain-containing adaptors define the specificity of TLR signaling. MolImmunol 40(12):861-868.

72. Zarember KA, Godowski PJ. 2002. Tissue expression of human Toll-like receptors and differential regulation of Toll-like receptor mRNAs in leukocytes in response to microbes, their products, and cytokines. J Immunol 168(2):554-561.

73. Vignola AM, Kips J, Bousquet J. 2000. Tissue remodelling as a feature of persistent asthma. J Allergy Clin Immunol 105(6 Pt 1):1041-1053.

74. Wang T, Town T, Alexopoulou L, Anderson JF, Fikrig E, Flavell RA. 2004. Toll- like receptor 3 mediates West Nile virus entry into the brain causing lethal encephalitis. Nat Med 10(12):1366-1373.

75. Takeda K, Kaisho T, Akira S. 2003. Toll-like receptors. AnnuRevImmunol 21:335-376.

76. Wagner H. 2001. Toll meets bacterial CpG-DNA. Immunity 14(5):499-502.

77. Syed TA, Hadi SM, Qureshi ZA, Ali SM, Kwah MS. 2000. Treatment of external genital warts in men with imiquimod 2% in cream. A placebo-controlled, double-blind study. JInfect 41(2):148-151.

78. Stowell NC, Seideman J, Raymond HA, Smalley KA, Lamb RJ, Egenolf DD, Bugelski PJ, Murray LA, Marsters PA, Bunting RA, Flavell RA, Alexopoulou L, San Mateo LR, Griswold DE, Sarisky RT, Mbow ML, Das AM. 2009. Long-term activation of TLR3 by poly(I:C) induces inflammation and impairs lung function in mice. Respir Res 10:43.

79. Wong WS. 2005. Inhibitors of the tyrosine kinase signaling cascade for asthma. Curr Opin Pharmacol 5(3):264-271.

80. Shirakawa T, Enomoto T, Shimazu S, Hopkin JM. 1997. The inverse association between tuberculin responses and atopic disorder. Science 275(5296):77-79.

81. Temann UA, Ray P, Flavell RA. 2002. Pulmonary overexpression of IL-9 induces Th2 cytokine expression, leading to immune pathology. J Clin Invest 109(1):29-39.

82. Sovijarvi AR, Haahtela T, Ekroos HJ, Lindqvist A, Saarinen A, Poussa T, Laitinen LA. 2003. Sustained reduction in bronchial hyperresponsiveness with inhaled fluticasone propionate within three days in mild asthma: time course after onset and cessation of treatment. Thorax 58(6):500-504.

83. Werling D, Hope JC, Howard CJ, Jungi TW. 2004. Differential production of cytokines, reactive oxygen and nitrogen by bovine macrophages and dendritic cells stimulated with Toll-like receptor agonists. Immunology 111(1):41-52.

84. Yamaguchi Y, Hayashi Y, Sugama Y, Miura Y, Kasahara T, Kitamura S, Torisu M, Mita S, Tominaga A, Takatsu K. 1988a. Highly purified murine interleukin 5 (IL-5) stimulates eosinophil function and prolongs in vitro survival. IL-5 as an eosinophil chemotactic factor. J Exp Med 167(5):1737-1742.

85. Anti-ulcer treatment during pregnancy induces food allergy in mouse mothers and a Th2-bias in their offspring.

86. Wilson JW, Bamford TL. 2001. Assessing the evidence for remodelling of the airway in asthma. Pulm Pharmacol Ther 14(3):229-247.

87. Verzeichnis der Veröffentlichungen